# Halozyme Therapeutics (HALO) — Earnings

HALO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/halo/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $2.28 |
| EPS estimate | $1.79 |
| EPS surprise | +27.58% |
| Revenue surprise | +19.57% |
| Revenue | $481.0M |
| Revenue estimate | $402.3M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1159036/000115903626000104/halo-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/b30f689b-7d81-4c20-e13a-bace700f8693.html) |

Halozyme reported Q2 2026 results on August 6, 2026. Earnings per share were $2.28, beating the $1.79 estimate by 27.58%. Revenue reached $481.0 million against a $402.3 million consensus, a 19.57% beat. Both figures are the highest in the table. Compared with Q2 2025, EPS rose about 48% from $1.54 and revenue rose about 48% from $325.7 million.

The longer record shows strong growth with one break. Annual EPS rose from $1.45 in 2022 to $2.78 in 2023 and $4.23 in 2024, then slipped to $4.13 in 2025. That 2025 total includes a Q4 loss of $0.24 per share against a $2.16 estimate, even as revenue reached $451.8 million. Annual revenue grew each year, from $660.2 million in 2022 to $1.40 billion in 2025. The first half of 2026 brought $3.88 per share, about 46% more than a year earlier. Halozyme topped the EPS estimate in 16 of the last 20 quarters.

Halozyme reported Q3 between October 31 and November 8 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue stays near the Q2 level.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | $1.79 | $2.28 | 27.58% | $402.3M | $481.0M |
| Q1 2026 | May 11, 2026 | $1.55 | $1.60 | 3.56% | $358.6M | $376.7M |
| Q4 2025 | Feb 17, 2026 | $2.16 | −$0.24 | -111.11% | $435.7M | $451.8M |
| Q3 2025 | Nov 3, 2025 | $1.63 | $1.72 | 5.51% | $340.0M | $354.3M |
| Q2 2025 | Aug 5, 2025 | $1.27 | $1.54 | 21.42% | $285.9M | $325.7M |
| Q1 2025 | May 6, 2025 | $0.95 | $1.11 | 17.04% | $230.1M | $264.9M |
| Q4 2024 | Feb 18, 2025 | $1.16 | $1.26 | 8.78% | $285.7M | $298.0M |
| Q3 2024 | Oct 31, 2024 | $0.99 | $1.27 | 28.11% | $252.2M | $290.1M |
| Q2 2024 | Aug 6, 2024 | $0.76 | $0.91 | 19.96% | $204.9M | $231.4M |
| Q1 2024 | May 7, 2024 | $0.69 | $0.79 | 15.08% | $199.7M | $195.9M |
| Q4 2023 | Feb 20, 2024 | $0.83 | $0.82 | -0.61% | $231.0M | $230.0M |
| Q3 2023 | Nov 6, 2023 | $0.71 | $0.75 | 6.20% | $216.1M | $216.0M |
| Q2 2023 | Aug 8, 2023 | $0.63 | $0.74 | 17.46% | $200.0M | $221.0M |
| Q1 2023 | May 9, 2023 | $0.38 | $0.47 | 22.88% | $179.3M | $162.1M |
| Q4 2022 | Feb 21, 2023 | $0.30 | $0.42 | 40.61% | $192.1M | $181.5M |
| Q3 2022 | Nov 8, 2022 | $0.36 | $0.44 | 21.65% | $191.2M | $209.0M |
| Q2 2022 | Aug 9, 2022 | $0.47 | $0.16 | -65.96% | $138.6M | $152.4M |
| Q1 2022 | May 10, 2022 | $0.46 | $0.43 | -6.79% | $128.3M | $117.3M |
| Q4 2021 | Feb 22, 2022 | $0.38 | $0.46 | 19.57% | $101.5M | $102.0M |
| Q3 2021 | Nov 2, 2021 | $0.42 | $1.48 | 249.47% | $105.8M | $115.8M |

## Frequently Asked Questions

### When did Halozyme Therapeutics (HALO) last report earnings?

Halozyme Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did HALO beat earnings estimates?

Yes. Halozyme Therapeutics reported EPS of $2.28 for Q2 2026 against a $1.79 estimate — a 27.58% beat.

### How much revenue did HALO report last quarter?

Halozyme Therapeutics reported $481.0M in revenue for Q2 2026, against a consensus estimate of $402.3M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).